Axoltis Pharma has announced it has secured $18,000,000 in new investment from a recent funding round. The capital will support the ongoing development of NX210c, its pioneering treatment for Amyotrophic Lateral Sclerosis (ALS), a debilitating neurodegenerative disease. This funding marks a significant milestone for the company as it advances its therapeutic pipeline.
Axoltis Pharma is dedicated to addressing the critical unmet medical needs of patients suffering from ALS, also known as maladie de Charcot. ALS is characterized by the progressive destruction of motor neurons, leading to muscle weakness, paralysis, and ultimately death, with very limited existing treatment options. Their lead candidate, NX210c, is a targeted peptide designed to restore the blood-brain barrier (BBB), a key factor implicated in ALS and other neurodegenerative conditions. NX210c holds 7 patents and has been granted orphan drug designation in both the USA and the EU for ALS. The treatment is currently undergoing a Phase 2 clinical trial involving 80 patients, with topline results anticipated in April 2026.
The $18,000,000 investment is poised to significantly accelerate the development of NX210c. Axoltis Pharma plans to deploy these funds to advance its clinical trial programs, support regulatory preparations, and expand its research efforts into BBB restoration. This financial backing underscores investor confidence in Axoltis Pharma's innovative approach and its potential to deliver a groundbreaking solution for a devastating disease.
As a pioneer in BBB restoration, Axoltis Pharma is committed to bringing new hope to millions of patients facing neurodegenerative diseases. The company looks forward to leveraging this substantial capital to further its mission and move closer to making NX210c available to those in need, reinforcing its position at the forefront of neurodegenerative disease research.
.png&w=3840&q=75)
